Relay Therapeutics, Inc. (RLAY)
| Market Cap | 2.94B |
| Revenue (ttm) | 82.65M |
| Net Income (ttm) | -230.20M |
| Shares Out | 90.43M |
| EPS (ttm) | -5.40 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | April 20 |
| Last Price | $32.26 |
| Previous Close | $32.63 |
| Change ($) | -0.37 |
| Change (%) | -1.13% |
| Day's Open | 32.29 |
| Day's Range | 31.50 - 32.99 |
| Day's Volume | 214,572 |
| 52-Week Range | 30.72 - 64.37 |
Advanced two programs, RLY-1971 and RLY-4008, into clinical development, and on track to initiate IND enabling studies with PI3Kα mutant selective inhibitor in 2021
RLY-4008 demonstrates strong activity against known clinical on-target resistance mutations in cellular and in vivo preclinical models RLY-4008 demonstrates strong activity against known clinical on-tar...
CAMBRIDGE, Mass., Feb. 04, 2021 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY) is scheduled to participate in a fireside chat at the Guggenheim Healthcare Talks 2021 Oncology Day on Thursda...
CAMBRIDGE, Mass., Jan. 06, 2021 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY) is scheduled to present at the 39th Annual J.P. Morgan Healthcare Conference on Tuesday, January 12, 2021 at 4...
Collaboration brings together clinical stage SHP2 and KRAS G12C inhibitors
CAMBRIDGE, Mass., Nov. 12, 2020 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by leveraging unparallele...
Relay Therapeutics: Heavily Backed Biotech Brains Trust Looks A Long-Term Buy
CAMBRIDGE, Mass., Sept. 03, 2020 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by leveraging unparall...
CAMBRIDGE, Mass., Aug. 27, 2020 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by leveraging unparalle...
CAMBRIDGE, Mass., July 20, 2020 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by leveraging unparalle...
TAIPEI, Taiwan--(BUSINESS WIRE)--Oak Stone Limited says SoftBank-backed Relay Therapeutics has soared 75% in its trading debut, expanding its IPO to raise $400 million.
IPOS to watch: Relay Therapeutics and Trean Insurance Group
Yahoo Finance's Jared Blikre breaks down IPOs Relay Therapeutics and Trean Insurance Group.
Shares of Relay Therapeutics Inc. RLAY, +67.10% sprinted out of the gate Thursday, after the clinical-stage oncology company's upsized initial public offering priced above the expected range.
Relay Therapeutics raised $400 million with an initial public offering that priced late Wednesday and surpassed expectations. The Relay Therapeutics IPO will begin trading Thursday morning.
About RLAY
Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology. The company's lead product candidates include RLY-1971, an oral small molecule inhibitor of protein tyrosine phosphatase Src homology region 2 domain-containing phosphatase-2 that is in Phase 1 trial in patients with advanced solid tumors; RLY-4008, an oral small molecule selective inhibitor of fibroblast growth facto... [Read more...]
| Industry Biotechnology | IPO Date Jul 16, 2020 |
| Stock Exchange NASDAQ | Ticker Symbol RLAY |
Analyst Forecasts
According to 6 analysts, the average rating for RLAY stock is "Buy." The 12-month stock price forecast is 54.40, which is an increase of 68.63% from the latest price.